NCT02024217Unknown2 期
Phase II Study of Neoadjuvant Chemotherapy Wtih S1+Oxaliplatin (SOX) Regimen Followed by Chemoradiation Concurrent With S-1 in Patients With Potentially Resectable Gastric Carcinoma
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- R0 resection rate
研究概览
简要总结
To investigate the feasibility, safety and tolerability of Preoperative Chemoradiation in Patients With Localized Gastric Cancer. Primary endpoint: R0 resection rate. Secondary endpoint: resection rate, pathological complete regression (pCR), effectiveness and safety of regime, disease free survival(DFS) and overall survival(OS).
详细描述
The prognosis of gastric cancer is poor partially due to low R0 resection rate. Neoadjuvant chemoradiotherapy was reported to be effective in this setting by several phase II studies. The investigators aim to evaluate the efficacy and toxicity of neoadjuvant chemoradiotherapy in a prospective phase II study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.18 ≤ age ≤ 70, Male or Female; 2.Minimum life expectancy of 6 months; 3.Patients with localized, histologically confirmed gastric or gastroesophageal adenocarcinoma; 4.Patients must have a performance status of < 2 Eastern Cooperative Oncology Group (ECOG); 5.No prior major surgery of the stomach or radiation therapy to the stomach or immunotherapy or chemotherapy; 6.CT or MRI, endorectal ultrasonography (EUS), laparoscopic exploration are required to stage; 7.Without other benign diseases such as lung, kidney, liver infections; 8.Without participating other clinical trials; 9.Patient must sign an informed consent prior to study entry; 10.Patients must have adequate bone marrow function (defined as peripheral absolute granulocyte count of >1,500/µL, and platelet count of > 100,000/µL), adequate liver function (bilirubin <= 1.5 mg/dl), and adequate renal function (creatinine <= 1.5 mg/dl). 11)Patients without cardiac disease , severe uncontrolled diabetes, hypertension, cerebrovascular disease, or infection.
排除标准
- •Pregnant women are excluded from study entry due to the potential teratogenic effects of the study treatment;
- •Female patients who planed to have a baby;
- •Prior radiation therapy to the stomach, liver or kidney;
- •Dysfunction of important organs such as liver, kidney or heart; 5.Abnormalities of mental status;
- •6.Active coronary artery disease; 7.Cardiac arrhythmia, and need to receive medication therapy; 8.Severe uncontrolled hypertension; 9.Active clinical serious infection; 10.The known human immunodeficiency virus (HIV) infection history; 11.The known central nervous system diseases, including brain metastatic tumors; 12.Patients have had clinical clear gastrointestinal bleeding in 6 months; 13.Drug abuse; 14.Swallowing difficulties for drugs; 15.Poor compliance; 16.Presence of concurrent or previous malignancies (except for cervical carcinoma in situ or basal cell carcinoma of the skin); 17.Presence of peritoneal metastasis, distant organs or lymph nodes metastasis; 18.Presence history of major surgery in the past three months; 19.Poor tolerability; 20.Prior history of medication; 21.allergy for chemotherapeutic drugs.
结局指标
主要结局
R0 resection rate
时间窗: 6-8 Weeks
6-8 weeks after Radiation therapy，we evaluate the lesion，if it is resectable，we will give surgical therapy，
次要结局
- safety and tolerability of the treatment regimen(up to 10 weeks)
研究者
Zhen Zhang
Chairman of Department of Radiation Oncology Fudan University Shanghai Cancer Center
Fudan University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II study of pre-operative chemoradiation using S-1 followed by surgical resection for potentially resectable and locally advanced pancreatic cancerPotentially resectable and locally advanced pancreatic cancerJPRN-UMIN000003088Department of Surgery, Kansai Medical University Hirakataka Hospital30
Unknown
2 期
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal CancerEsophageal NeoplasmsConcurrent ChemoradiotherapySquamous Cell CarcinomaNCT03579004Mona Frolova48
Unknown
2 期
Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT01054482The First Affiliated Hospital of Guangzhou Medical University120
已完成
2 期
Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx CancerOropharynx CancerNCT03838263UNICANCER62
进行中（未招募）
1 期
Chemoradiotherapy plus avelumab in locally advanced rectal cancerocally advanced rectal cancerMedDRA version: 20.0Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003582-10-ITG.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST101